Jane Street’s Adverum Biotechnologies ADVM Stock Holding History

Jane Street’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,760	Closed	-$60K	–	9980
2021 Q3	$60K	Buy	2,760 +1,020	+59%	+$26K	﹤0.01%	9487
2021 Q2	$61K	Buy	+1,740	New	+$93.7K	﹤0.01%	9450
2020 Q3	–	Sell	-1,230	Closed	-$257K	–	7077
2020 Q2	$257K	Buy	+1,230	New	+$218K	﹤0.01%	6052

Other funds holding ADVM

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

PWA

Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Jane Street's ADVM Position: Q3 2025 in Review

Jane Street sold out of Adverum Biotechnologies (ADVM) in Q3 2025, closing a stake of 70,931 shares — an estimated $153K sold.

Jane Street first reported a position in ADVM in Q3 2017 and held it in 18 quarters. The position peaked at $1.51M in Q2 2020. 50 funds tracked by Wall St. Rank hold ADVM as of Q3 2025.

Jane Street reported no remaining Adverum Biotechnologies position as of Q3 2025 after selling out during the quarter.
Jane Street sold 70,931 Adverum Biotechnologies shares in Q3 2025, an estimated $153K.
Jane Street first reported a position in Adverum Biotechnologies in Q3 2017 and held it in 18 quarters.
Jane Street's Adverum Biotechnologies position peaked at $1.51M in Q2 2020.
50 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2025.

Based on Jane Street's 13F filing for Q3 2025, filed 14 Nov 2025.